Pharmacologic class: Natural lung surfactant

Therapeutic class: Lung surfactant

Pregnancy risk category NR


Adsorbs rapidly to air: liquid interface of lung alveoli, stabilizing and modifying surface tension. Restores adequate pressure volumes, gas exchange, and overall lung compliance.


Suspension for intratracheal injection: 6 ml in single-dose vials

Indications and dosages

To prevent respiratory distress syndrome (RDS) in at-risk premature infants; treatment of infants who develop RDS

Premature infants: 3 ml/kg at birth intratracheally q 12 hours, up to three doses. Initial dose must be administered as two 1.5-ml/kg doses.




Use cautiously in:

• altered ventilation requirements

• risk of cyanosis, bradycardia, or airway obstruction.


Know that drug is intended for intratracheal administration and should be given only by neonatologists or other clinicians experienced in neonatal intubation and ventilatory management in facilities with adequate personnel, equipment, and drugs.

Don't dilute drug or shake vial.

• Be aware that drug must be drawn into syringe through 20G or larger needle, taking care to avoid excessive foaming. Needle must be removed before drug is delivered through endotracheal tube.

Know that infant must receive continuous monitoring before, during, and after drug administration.

Adverse reactions

CV: bradycardia

Respiratory: requirement for manual ventilation or reintubation, airway obstruction, reflux of drug into endotracheal tube, cyanosis


None significant

Patient monitoring

Monitor infant's respiratory status continuously during and after drug administration.

Patient teaching

• Teach parents about treatment and assure them that infant will be monitored carefully.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved


Calfactant Neonatology A suspension administered intratracheally to prevent RDS in high-risk premature infants < 29 wks of gestational age who require endotracheal intubation. See Respiratory distress syndrome.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
Mentioned in ?
References in periodicals archive ?
However, we and others have found the same equilibrium, minimum and maximum surface tension of a range of surfactant concentrations (0.5 to 28 mg/ml), surfactant preparations (Infasurf, BLES and Curosurf[R]) and method of analysis (pulsating bubble surfactometer, captive bubble surfactometer or CDS) (Bachofen et al., 2005; Acosta et al., 2007; Zuo et al., 2008; Valle et al., 2014, 2015).
While nasal CPAP was continued in one group, calfactant (Infasurf) was administered by laryngeal mask and subsequently nasal CPAP was inititated in the other group.
Curosurf Poractant alpha Alveofact SF-RI 1 BLES Bovine Lipid Extract Surfactant Infasurf Calfactant CLSE Newfacten ?
In addition to colfosceril and beractant, the other two FDA-approved surfactants are poractant alpha (Curosurf) and calfactant (Infasurf).
The independent analysis, which was published in the eFirst Pages section of the Pediatrics website, was aimed at comparing the efficacy of CUROSURF versus Survanta (beractant) and Infasurf (calfactant) with respect to clinical outcomes among preterm infants with RDS.
De acuerdo con los datos encontrados en los recien nacidos menores de 1500 gramos, el surfactante cuyos pacientes presentaron un menor porcentaje de displasia fue el survanta con un 66%, seguido por el curosurf con un 70% y el infasurf con un 75%.
The biological surfactant preparation Infasurf (calfactant) was a natural lung-ravage surfactant derived from calf lung that required no reconstitution.
Medications administered during the weeks of testing consisted of caffeine, ampicillin, gentamicin, and Infasurf. No surgeries were performed until after the test sessions were completed, when a VP shunt was placed.
Four large (several hundred in each group), prospective randomized clinical trials comparing Exosurf (synthetic, no apoproteins) to Survanta (beractant) and to Infasurf (calfactant) have been conducted.
5 December 2011 - ONY Inc, the producer of Infasurf which is used to treat premature infants against Respiratory Distress Syndrome, filed a lawsuit against Cornerstone Therapeutics (NASDAQ:CRTX) and its parent firm, Chiesi Farmaceutici SpA, of providing manipulated data to claim the use of its competing drug, Curosurf, leads to lower mortality rates.
Examples of natural surfactant include Beractant (Survanta), Poractant Alfa (Curosurf), and Clafactant (Infasurf)
There was no difference in mortality when surfactants Infasurf and Survanta were used in neonates less than 36 weeks' estimated gestation, reported Dr.